Skip to main content

6-K

COSCIENS Biopharma Inc. (CSCIF)

6-K 2022-07-19 For: 2022-07-19
View Original
Added on April 06, 2026

UNITEDSTATES

SECURITIESAND EXCHANGE COMMISSION

Washington,D.C. 20549


FORM6-K


REPORTOF FOREIGN PRIVATE ISSUER

PURSUANTTO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934


For the month of July 2022

Commission File Number: 001-38064

AeternaZentaris Inc.

(Translation of registrant’s name into English)

c/oNorton Rose Fulbright Canada, LLP, 222 Bay Street, Suite 3000, PO Box 53, Toronto ON M5K 1E7

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Exhibits 99.1 and 99.2 included with this report on Form 6-K are hereby incorporated by reference into the Registrant’s Registration Statements on Forms S-8 (No. 333-224737, No. 333-210561 and No. 333-200834), Forms F-3 (No.333-232935 and No. 333-254680) and Forms F-1 (No.333-239264, No. 333-248561 and No. 333-239019)and shall be deemed to be a part thereof from the date on which this report is furnished, to the extent not superseded by documents or reports subsequently filed or furnished.

DOCUMENTSINDEX

Exhibit Description
99.1 Aeterna Zentaris Inc – Amendment to the Articles of Incorporation
99.2 Aeterna Zentaris Inc – Confirmation of Letter of Transmittal
| \(2\) |

| --- |

SIGNATURE


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AETERNA ZENTARIS INC.
Date:<br> July 19, 2022 By: /s/ Klaus Paulini
Klaus<br> Paulini
President<br> and Chief Executive Officer
| \(3\) |

| --- |




****


****


****